Iclusig Approved for Rare Leukemias
FRIDAY, Dec. 14 (HealthDay News) -- Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia -- cancers of the blood and bone marrow.
The drug was sanctioned for adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), the FDA said Friday in a news release.
Iclusig blocks the effects of proteins that promote development of cancer cells, the agency said. The drug was granted accelerated approval following a single study of 449 people with either CML or Ph+ ALL.
The product's label will include a boxed warning that users are at heightened risk of blood clots and liver poisoning. More common but less serious clinical side effects included high blood pressure, rash, abdominal pain, fatigue, headache, dry skin, constipation, fever, joint pain and nausea.
Iclusig is marketed by Ariad Pharmaceuticals, based in Cambridge, Mass.
More information
The FDA has more about this approval.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
Health News Today
Feed- Gene Discovery May Offer Breakthrough for Rare Leukemia 05/09/2013
- Scientists Pinpoint Most Major Genes Behind Deadly Blood Cancer 05/01/2013
- Water Pipe No Safer Than Cigarettes: Study 04/29/2013
- Soaring Prices Keep Leukemia Drugs From Patients, Experts Say 04/25/2013
- New Strategy Helps Young Lymphoma Patients Avoid Radiation Treatment 04/10/2013
- View More Leukemia News
Popular Features
Your Guide to Leukemia
Take a Personalized Health Test
How well are you controlling your symptoms?
What's Causing Your Symptoms?
15 Ways To Get Better Medicine
People who are actively involved in their medical care stay healthier, recover quicker when they're ill, and live longer, healthier lives.